Table 2.
Anticoagulant use outcomes in the study period
| IMS | MarketScan Commercial | MarketScan Medicare | Optum | Medicaid | |
|---|---|---|---|---|---|
|
All patients, N |
30,757 |
21,976 |
38,643 |
9,120 |
4,901 |
|
Patients receiving anticoagulant by stroke risk* and age category, N (%) |
|
|
|
|
|
| All Stroke Risk Levels |
11,382 (37%) |
6,444 (29%) |
14,686 (38%) |
3,595 (39%) |
803 (16%) |
| High Risk |
6,832 (43%) |
1,934 (39%) |
9,822 (40%) |
1,946 (51%) |
566 (19%) |
| Age <65 years |
1,252 |
1,877 |
58 |
672 |
476 |
| Age: 65–74 years |
1,484 |
57 |
1,651 |
386 |
38 |
| Age ≥ 75 years |
4,090 |
0 |
8,113 |
888 |
52 |
| Moderate Risk |
3,130 (34%) |
2,415 (31%) |
3,788 (36%) |
1,091 (36%) |
172 (13%) |
| Age <65 years |
1,149 |
2,311 |
34 |
696 |
158 |
| Age: 65–74 years |
1,213 |
104 |
1,600 |
292 |
11 |
| Age ≥ 75 years |
764 |
0 |
2,154 |
103 |
3 |
| Low Risk |
1,420 (25%) |
2,095 (23%) |
1,076 (33%) |
558 (25%) |
65 (12%) |
| Age <65 years |
813 |
1,940 |
12 |
423 |
63 |
| Age: 65–74 years |
603 |
155 |
1,064 |
135 |
2 |
| Age ≥ 75 years |
0 |
0 |
0 |
0 |
0 |
|
Anticoagulant MPR |
|
|
|
|
|
| MPR |
0.58 |
0.58 |
0.66 |
0.61 |
0.72 |
|
Gap in Anticoagulation Therapy |
|
|
|
|
|
| Patients with a Gap in Anticoagulation Therapy, N(%) |
6,745 (59%) |
3,828 (59%) |
6,687 (46%) |
1,883 (52%) |
233 (29%) |
| Average Time to First Gap in Anticoagulation Therapy (days) | 132 | 150 | 157 | 144 | 129 |
MPR – Medication Possession Ratio.
*CHADS2 used to determine stroke risk.